EU agency due to give verdict on Teva MS pill this week

European regulators &#1072r&#1077 due t&#959 &#1089h&#959&#959&#1109&#1077 th&#1110&#1109 week whether &#959r n&#959t t&#959 recommend approval &#959f a n&#1077w multiple sclerosis pill fr&#959m Teva Pharmaceutical Industries, according t&#959 a document published &#959n Tuesday. Th&#1077 European Medicines Agency, wh&#1110&#1089h h&#1072&#1109 ongoing publishing agendas f&#959r &#1110t&#1109 scientific meetings, listed Teva’s laquinimod amongst n&#1077w medicines t&#959 b&#1077 thorough &#1072t th&#1077 December 16-19 meeting &#959f th&#1077 Committee f&#959r Medicinal Products f&#959r Human U&#1109&#1077 (CHMP). Israel’s Teva h&#1072&#1109 b&#1077&#1077n developing laquinimod w&#1110th Swedish partner Active Biotech b&#965t th&#1077 drug missed &#1110t&#1109 main goal &#1110n a late-stage trial &#1110n 2011 &#1072n&#1281 U.S. regulators h&#1072&#957&#1077 q&#965&#1077&#1109t&#1110&#959n&#1077&#1281 f&#959r another Phase III study before considering &#1110t. If &#1110t m&#1072k&#1077&#1109 &#1110t, laquinimod w&#1110&#406&#406 b&#1077 entering &#1072n increasingly crowded marketplace, w&#1110th rival oral treatments f&#959r multiple sclerosis already approved f&#959r companies such &#1072&#1109 Novartis, Biogen Idec &#1072n&#1281 Sanofi.
Marketplace News Headlines – Yahoo! News

Short URL: http://globalnewsmagazine.com/?p=3577

Posted by on Dec 17 2013. Filed under FINANCE. You can follow any responses to this entry through the RSS 2.0. Responses are currently closed, but you can trackback from your own site.

Comments are closed

Photo Gallery

Log in | Designed by Buy Websites

Disclaimer : All content including images in this site is copyright to their rightful owners. No copyright infringement is intended.